Clinical Trial Update: Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma [EARLY_Phase 1]

View source ↗

Summary

Early-phase, intralesional nivolumab therapy for limited cutaneous Kaposi sarcoma in HIV/AIDS patients has completed its Phase 1 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Aids
• Kaposi Sarcoma

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Kaposi Sarcoma, HIV/AIDS | EARLY_Phase 1 | Status: COMPLETED